(RTTNews) - Hanmi Pharm. Co., Ltd. (128940.KS), a South Korean biopharmaceutical and manufacturing company, on Tuesday reported a decline in net income despite higher sales in the third quarter of 2026 compared with the previous year.
Publicznie pokazujemy glowna mysl. Utworz darmowe konto, aby czytac caly artykul, zapisac go, omowic i polaczyc z kontekstem rynkowym oraz OSINT.